George Yu focuses his practice on intellectual property, with an emphasis on patent infringement and technology-related trade secret misappropriation. Mr. Yu’s strong background in biochemistry and molecular biology enhance his experience in handling matters involving complex biotechnology and medical technology products. Mr. Yu also has extensive industry experience in handling matters involving Technology, Software Products, and Healthcare.

Experience

Mr. Yu's vast experience is highlighted with the following matters:

• Assistant general counsel for a research leader, developer, manufacturer and worldwide distributor of microarray technology used in analyzing complex genetic information, where he defended the company against claims of patent infringement, including: a matter of patent infringement which ended with a successful summary judgment on non-infringement and was affirmed on appeal; the successful defense of another claim of patent infringement which led to a favorable settlement; and patent litigation work in the District of Delaware where the opposing party was found to have infringed five of the company's patents and paid the company $95 million as part of a settlement.
• Successful trial team member that obtained judgment of obviousness in an ANDA litigation in the District of New Jersey.
• Successful trial team member in a high-stakes patent matter in the District of Delaware involving recombinant Human Factor VIII resulting in the dismissal of all claims against his clients in an opinion that was recently affirmed by the Court of Appeals for the Federal Circuit.
• Obtained a pre-answer dismissal for an electronics company in a patent infringement action in the Northern District of California.
• Defended a semiconductor company in a patent infringement action in the Western District of Washington and helped to negotiate a favorable settlement.
• Defended an online matchmaking company in a patent infringement action in the Eastern District of Texas and helped to negotiate a favorable settlement.
• Led the technical and scientific aspects of a high-profile patent infringement case involving monoclonal antibody technology on behalf of one of the world's leading developers of tools, products and services used to screen blood and ensure blood safety in the transfusion industry.
• Represented a global manufacturing company in a copyright infringement litigation in the Northern District of California and was successful in compelling arbitration in Sweden of a breach of contract claim involving enterprise software.
• A three-week long bench trial of a trade secret misappropriation matter involving the theft of FDA manuals and cells used to make monoclonal antibodies, in which he represented the plaintiff resulting in a multi-million dollar verdict in favor of his client which was affirmed on appeal.
• Representing the plaintiff, a non-profit research institute, in a jury trial involving ownership of patents relating to nucleic acid detection technology.

Publications

"Forecasting the U.S. High Court's Gene Patentability Ruling," (co-author) The Daily Journal (May 8, 2013)

"Federal Trade Commission v. Actavis, Inc: A Quick Look into Reverse Payments," Spicy IP (March 22, 2013)

"The 'Safe Harbor' May Be Safer than Expected—Or Maybe Not: The Conflict Created by Momenta Pharmaceuticals v. Amphastar Pharmaceuticals," (co-author) Bloomberg/BNA Pharmaceutical Law & Industry Report (August 24, 2012)

"The Supreme Court's Mayo v. Prometheus Decision: The Implications for Biotechnology," (co-author) The National Law Review (March 23, 2012)

"Justices Weigh in on Patents for Personalized Medicine," (co-author) San Francisco Daily Journal (April 2, 2012)

"How the First-To-File Provisions of the America Invents Act Will Affect Biotechnology," San Francisco Daily Journal (February 1, 2012)

"The Scope of Patentable Subject Matter After 'Bilski'," (co-author)
National Law Journal (January 31, 2011)

"A Framework for Protecting Innovations in Personalized Medicine,"
(co-author) Life Sciences Law & Industry (February 27, 2009)

"Redefining Obviousness After KSR Decision," (co-author)
Genetic Engineering & Biotechnology News (October 2008)

"Case Comment: United States," Patent World (co-author)
(June/July 1999)

"Injunctive Relief in Patent Litigation," (co-author) Patent Litigation Handbook (Practising Law Institute, November 1996)

Speeches and Presentations

"Hatch-Waxman and BPCIA 101 – A Primer on IP Basics and Regulatory Fundamentals," American Conference Institute's Seventh Annual Paragraph IV Disputes, New York, N.Y. (May 6, 2013)

"A Glimpse of the Future – US Biosimilars Litigation Considerations," Biopractice.com webinar (December 15, 2011)

Previous Experience

Before joining Schiff Hardin, Mr. Yu was a counsel for another large law firm in San Francisco. He began his legal career as an associate with other international law firms in the San Francisco area.